세계의 GLP-1 작용제 시장 : 제품별, 분자별, 유형별, 적응증별, 제형별, 투여 경로별, 최종사용자별, 지역별 - 예측(-2033년)

The GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period. The GLP-1 agonists market has expanded rapidly due to several key drivers. One prominent factor is the growing number of new indication approvals for GLP-1 drugs by regulatory agencies. These approvals extend the uses of GLP-1 agonists beyond initial indications, allowing for treatments in broader patient populations, including newer indications such as cardiovascular conditions, Alzheimer's disease, obstructive sleep apnea, and obesity.

The rising prevalence of these chronic conditions globally further supports strong market growth, as more patients require effective therapies for diabetes and obesity. In parallel, GLP-1 agonists offer proven clinical benefits such as improved glycemic control and significant weight reduction, increasing their adoption rates among healthcare providers.

The patented products segment accounted for the largest share of the GLP-1 agonists market by type in 2024.

Based on type, the GLP-1 agonists market is segmented into patented products and biosimilars. In 2024, the patented products accounted for the largest share of the market. As biosimilars are expected to gain adoption post-2026, patented products currently account for the complete market. However, with the semaglutide patent expiring in 2026 onwards, the market for biosimilars is expected to grow significantly thereafter. Patented GLP-1 agonists dominate prescribing patterns due to their robust clinical data, extensive safety profiles, and premium marketing investments. Additionally, the original GLP-1 makers have established broad insurance coverage, ensuring patient access despite high list prices. These factors are expected to support market growth.

By end user, the home-care settings and fitness/ weight management facilities accounted for the largest share in the GLP-1 agonists market in 2024.

Based on end user, the GLP-1 agonists market is segmented into home-care settings and fitness/ weight management facilities, long-term care facilities, and hospitals & specialty clinics. In 2024, the home-care settings and fitness/weight management facilities segment accounted for the largest share of the GLP-1 agonists market. The large share of this end-user segment can be attributed to the evolving patient needs and broader trends in obesity and diabetes management. Home care settings offer convenience and flexible dosing schedules for patients, especially as most GLP-1 therapies are available in easy-to-administer, subcutaneous or oral formats. This increases patient adherence, with many preferring to self-administer medications, particularly for long-term therapies targeting obesity and type 2 diabetes. The spike in obesity prevalence and the mainstreaming of preventive health have also made GLP-1 usage in home environments much more common, driving share growth in this segment.

The US dominated the GLP-1 agonists market in 2024.

In 2024, the US dominated the GLP-1 agonists market due to a convergence of demographic, healthcare, regulatory, and commercial factors. The US has one of the highest prevalence rates globally for both obesity and type 2 diabetes, which significantly expands the patient pool eligible for GLP-1 treatment. Advanced healthcare infrastructure and widespread physician awareness ensure swift adoption of new therapies, while robust insurance coverage and reimbursement help broad patient access.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply-side- 70% and Demand-side 30%
• By Designation: Managers - 45%, CXOs & Directors - 30%, and Executives - 25%
• By Region: North America - 40%, Europe -25%, Asia Pacific -25%, Latin America -5% and the Middle East & Africa- 5%

List of Companies Profiled in the Report:

• Novo Nordisk A/S (Denmark)
• Eli Lilly and Company (US)
• Sanofi (France)
• Hansoh Pharmaceutical Group Co., Ltd. (China)
• Boehringer Ingelheim International GmbH (Germany)
• Innovent (China)
• Sun Pharmaceutical Industries Ltd. (India)
• Pegbio Co. Ltd (China)
• Structure Therapeutics (US)
• Viking Therapeutics (US)
• Amgen Inc. (Switzerland)
• Altimmune (US)
• Glenmark (India)
• Biocon (India)
• Teva Pharmaceuticals (Israel)
• Terns Pharmaceuticals, Inc. (US)
• VTV Therapeutics (US)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Hanmi Pharm Co., Ltd. (South Korea)
• Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)
• Pfizer Inc. (US)
• MetaVia Inc (US)
• SCOHIA PHARMA, Inc. (Japan)
• Sciwind Biosciences Co., Ltd. (China)
• i2o Therapeutics, Inc. (US)
• Biomed Industries, Inc. (US)
• Neuraly Inc. (US)

Research Coverage

This research report categorizes the GLP-1 agonists market by product (ozempic, wegovy, mounjaro, zepbound, rybelsus, trulicity, orforglipron, cagrisema, survodutide, retatrutide, semaglutide biosimilars, other GLP-1 biosimilars, other products), molecule (Semaglutide, Tirzepatide, Dulaglutide, Cagrilintide semaglutide combination, Orforglipron, Survodutide, Retatrutide, Other molecules), type (patented, biosimilars), format (single-dose, multi-dose, tablets), indication (diabetes, obesity, other indications), route of administration (subcutaneous, oral), end user (home-care settings and fitness/ weight management facilities, long-term care facilities, and hospitals and specialty clinics) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report's scope covers detailed information regarding the leading factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the GLP-1 agonists market. A thorough analysis of the key industry players has provided insights into their business overview, products offered, key strategies, collaborations, partnerships, and agreements. Product launches & approvals, expansions, acquisitions, partnerships, product pipelines, collaborations, and agreements are the recent developments associated with the GLP-1 agonists market.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall GLP-1 agonists market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (expanding manufacturing capacity, shift of GLP-1 drugs from diabetes specialty to broader treatment option, growing prevalence of obesity and type 2 diabetes), restraints (stringent cost and payer controls), opportunities (increasing studies on oral GLP-1), and challenges (counterfeits and compounded GLP-1 gray market, safety, tolerability, persistence issues) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly approved and launched products of the GLP-1 agonists market
• Market Development: Comprehensive information about lucrative markets - the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the GLP-1 agonists market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of key players, including Novo Nordisk (Denmark), Eli Lilly (US), and Sanofi (France), among other players. A detailed analysis of the key industry players has been conducted to provide insights into their key strategies, product approvals and launches, acquisitions, partnerships, agreements, collaborations, expansions, recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 agonists market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries
    • 2.1.2.2 Key objectives of primary research
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
  • 2.2.2 SECONDARY DATA & PRIMARY INTERVIEWS
  • 2.2.3 SEGMENTAL MARKET SIZE ASSESSMENT
• 2.3 MARKET GROWTH FORECAST
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY

• 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS
• 3.3 DISRUPTIVE TRENDS SHAPING GLP-1 AGONISTS MARKET
• 3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS

4 PREMIUM INSIGHTS

• 4.1 GLOBAL GLP-1 AGONISTS MARKET SNAPSHOT
• 4.2 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION AND COUNTRY, 2024
• 4.3 GLP-1 AGONISTS MARKET, BY FORMAT, 2024
• 4.4 GLP-1 AGONISTS MARKET, BY END USER, 2024
• 4.5 GLP-1 AGONISTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.6 UNMET NEEDS & WHITE SPACES
• 4.7 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
  • 4.7.1 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
• 4.8 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
• 4.9 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.10 GLP-1 AGONISTS PRODUCTION CAPACITY HIGHLIGHTS
• 4.11 KEY DRUG LAUNCHES EXPECTED, 2025-2033
• 4.12 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Expanding manufacturing capacities of large pharmaceutical companies
    • 5.2.1.2 Shift of GLP-1 drugs from diabetes specialty to broader treatment options
    • 5.2.1.3 Rising prevalence of obesity and type-2 diabetes
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Stringent cost and payer controls
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing studies on oral GLP-1
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Counterfeits and compounded GLP-1 gray market
    • 5.2.4.2 Safety, tolerability, and persistence issues
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.3.1 KEY GLP-1 AGONISTS PIPELINE & EXPECTED LAUNCHES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.4.2 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.4.3 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY REGION, 2022-2024
  • 5.4.4 FACTORS IMPACTING GLP-1 AGONISTS PRICING
• 5.5 INDUSTRY TRENDS
  • 5.5.1 SHIFT OF WEEKLY INJECTABLES TOWARD ORALS AND MULTI-AGONISTS
  • 5.5.2 VERTICAL INTEGRATION AND CAPACITY SCALE-UP TO MEET DEMAND
• 5.6 TECHNOLOGY ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 Chemical synthesis
    • 5.6.1.2 Recombinant DNA technology
  • 5.6.2 COMPLEMENTARY TECHNOLOGIES
    • 5.6.2.1 Peptelligence
    • 5.6.2.2 PEGylation and polymer encapsulation
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Hydrogel depot technologies
    • 5.6.3.2 Technologies for oral delivery of GLP-1 analogues
• 5.7 PIPELINE ANALYSIS
• 5.8 TECHNOLOGY/PRODUCT ROADMAP
• 5.9 VALUE CHAIN ANALYSIS
• 5.10 ECOSYSTEM ANALYSIS
  • 5.10.1 ROLE IN ECOSYSTEM
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 THREAT OF SUBSTITUTES
  • 5.11.3 BARGAINING POWER OF SUPPLIERS
  • 5.11.4 BARGAINING POWER OF BUYERS
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 REGULATORY ANALYSIS
  • 5.12.1 REGULATORY LANDSCAPE
  • 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.13 KEY CONFERENCES & EVENTS, 2025-2026
• 5.14 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 KEY BUYING CRITERIA
  • 5.14.3 ADOPTION BARRIER & INTERNAL FRICTION
• 5.15 INVESTMENT/FUNDING SCENARIO
• 5.16 REIMBURSEMENT SCENARIO
• 5.17 IMPACT OF AI/GEN AI ON GLP-1 AGONISTS MARKET
  • 5.17.1 IMPACT AT DEVELOPMENT AND MANUFACTURING STAGES
  • 5.17.2 AI USE CASES
  • 5.17.3 KEY COMPANIES IMPLEMENTING AI
  • 5.17.4 FUTURE OF AI/GEN AI IN GLP-1 AGONIST DRUG DEVELOPMENT ECOSYSTEM
• 5.18 IMPACT OF 2025 TRUMP TARIFF ON GLP-1 AGONISTS MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 IMPACT ON REGION
    • 5.18.4.1 North America
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Hospitals & specialty centers
    • 5.18.5.2 Long-term care facilities

6 GLP-1 AGONISTS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 GLP-1 AGONISTS VOLUME MARKET ESTIMATION
• 6.3 OZEMPIC
  • 6.3.1 ANTICIPATED PATENT EXPIRY OF SEMAGLUTIDE STARTING IN 2026 AND EXPECTED NEW DRUG LAUNCHES TO NEGATIVELY IMPACT MARKET
• 6.4 TRULICITY
  • 6.4.1 LOSS OF PATENT EXCLUSIVITY AND HIGH COMPETITIVE PRESSURE TO DISRUPT MARKET GROWTH
• 6.5 MOUNJARO
  • 6.5.1 DUAL MECHANISM AS BOTH GIP AND GLP-1 RECEPTOR AGONIST TO PROPEL ADOPTION
• 6.6 WEGOVY
  • 6.6.1 INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT MARKET GROWTH
• 6.7 RYBELSUS
  • 6.7.1 EASE OF ADMINISTRATION TO FUEL ADOPTION AMONG PATIENTS
• 6.8 ZEPBOUND
  • 6.8.1 INCREASED FOCUS ON OBESITY MANAGEMENT TO INDICATE HUGE GROWTH POTENTIAL
• 6.9 ORFORGLIPRON
  • 6.9.1 ORFORGLIPRON TO GAIN HIGH POTENTIAL DUE TO DEVICE-FREE LOGISTICS AND NO FASTING WINDOW
• 6.10 CAGRISEMA
  • 6.10.1 FOCUS ON CHRONIC WEIGHT MANAGEMENT AND TYPE 2 DIABETES TREATMENT TO SPUR MARKET GROWTH
• 6.11 SURVODUTIDE
  • 6.11.1 STRONG CLINICAL EFFICACY IN OBESITY AND METABOLIC DISEASE MANAGEMENT TO AID MARKET GROWTH
• 6.12 RETATRUTIDE
  • 6.12.1 STRONG WEIGHT-LOSS SIGNALS IN PHASE-2 DIABETES AND GLOBAL PHASE-3 CLINICAL PIPELINE TO DRIVE MARKET
• 6.13 SEMAGLUTIDE BIOSIMILARS
  • 6.13.1 HIGH DEMAND FOR AFFORDABLE DIABETES AND OBESITY TREATMENTS TO AID GROWTH
• 6.14 OTHER GLP-1 BIOSIMILARS
• 6.15 OTHER PRODUCTS

7 GLP-1 AGONISTS MARKET, BY MOLECULE

• 7.1 INTRODUCTION
• 7.2 SEMAGLUTIDE
  • 7.2.1 PROVEN EFFICACY IN SIGNIFICANT WEIGHT LOSS AND GLYCEMIC CONTROL TO SUPPORT GROWTH
• 7.3 TIRZEPATIDE
  • 7.3.1 STRONG EFFECTIVENESS IN OBESITY TREATMENT TO ENHANCE PHYSICIAN CONFIDENCE AND PAYER INTEREST
• 7.4 DULAGLUTIDE
  • 7.4.1 USAGE IN PEDIATRIC TYPE 2 DIABETES FOR PATIENTS OVER 10 YEARS OLD TO ENHANCE USAGE IN SPECIALTY SETTINGS
• 7.5 CAGRILINTIDE SEMAGLUTIDE COMBINATION
  • 7.5.1 SIGNIFICANT CLINICAL OUTCOMES IN WEIGHT MANAGEMENT TO DRIVE MARKET GROWTH
• 7.6 ORFORGLIPRON
  • 7.6.1 NEEDLE-FREE ALTERNATIVE TO INCREASE CONVENIENCE AND SUPPORT ADOPTION AMONG PATIENTS
• 7.7 SURVODUTIDE
  • 7.7.1 DUAL GCG/GLP-1 RECEPTOR AGONISM AND FAVORABLE CLINICAL EVIDENCE TO AID GROWTH
• 7.8 RETATRUTIDE
  • 7.8.1 TRIPLE-AGONIST APPROACH AND BEST-IN-CLASS WEIGHT MANAGEMENT FOR OBESITY TO SHOW HIGH GROWTH POTENTIAL
• 7.9 OTHER MOLECULES

8 GLP-1 AGONISTS MARKET, BY TYPE

• 8.1 INTRODUCTION
• 8.2 PATENTED PRODUCTS
  • 8.2.1 PATENTED GLP-1 BRANDS TO SHIFT FROM WEIGHT LOSS DRUGS TO CARDIOMETABOLIC THERAPIES FOR BETTER ACCESS AND DURABILITY
• 8.3 BIOSIMILARS
  • 8.3.1 SEMAGLUTIDE BIOSIMILARS
    • 8.3.1.1 Upcoming patent expiry for major drugs in key markets to increase biosimilar adoption
  • 8.3.2 OTHER BIOSIMILARS

9 GLP-1 AGONISTS MARKET, BY INDICATION

• 9.1 INTRODUCTIONS
• 9.2 DIABETES
  • 9.2.1 HIGH DIABETES PREVALENCE TO FUEL MARKET ADOPTION
• 9.3 OBESITY
  • 9.3.1 STRONG PIPELINE OF ANTI-OBESITY GLP-1 DRUGS TO DRIVE MARKET
• 9.4 OTHER INDICATIONS

10 GLP-1 AGONISTS MARKET, BY FORMAT

• 10.1 INTRODUCTION
• 10.2 SINGLE-DOSE FORMATS
  • 10.2.1 EASE OF ADMINISTRATION, DOSING AMOUNT PRECISION, AND LOW CONTAMINATION RISK TO SUPPORT MARKET GROWTH
• 10.3 MULTI-DOSE FORMATS
  • 10.3.1 COST-EFFECTIVENESS AND LOW MEDICAL WASTE GENERATION TO AUGMENT ADOPTION IN HEALTHCARE SETTINGS
• 10.4 AUTOINJECTORS
  • 10.4.1 SIMPLIFIED INJECTION PROCESS WITH LOWER HUMAN ERRORS TO SUPPORT ADOPTION

11 GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION

• 11.1 INTRODUCTION
• 11.2 SUBCUTANEOUS ADMINISTRATION
  • 11.2.1 PEN INJECTORS
    • 11.2.1.1 Easy monitoring of volume and dosage strength to support adoption
  • 11.2.2 AUTOINJECTORS
    • 11.2.2.1 Simplified injection process with lower human errors to support adoption
• 11.3 ORAL ADMINISTRATION
  • 11.3.1 ELIMINATION OF NEEDLEPHOBIA AND EASE OF USE TO DRIVE COMPLIANCE

12 GLP-1 AGONISTS MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 HOME CARE SETTINGS AND FITNESS/ WEIGHT MANAGEMENT FACILITIES
  • 12.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
• 12.3 LONG-TERM CARE FACILITIES
  • 12.3.1 GROWING GERIATRIC POPULATION WITH CHRONIC DISEASES TO SUPPORT SEGMENT GROWTH
• 12.4 HOSPITALS & SPECIALTY CLINICS
  • 12.4.1 ORGANIZED ENVIRONMENT, PROFESSIONAL OVERSIGHT, AND ABILITY TO HANDLE COMPLEX PATIENT NEEDS TO DRIVE MARKET

13 GLP-1 AGONISTS MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 13.2.2 US
    • 13.2.2.1 US to dominate North American GLP-1 agonists market during forecast period
  • 13.2.3 CANADA
    • 13.2.3.1 Favorable funding scenario and presence of strong research infrastructure to support market growth
• 13.3 EUROPE
  • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 13.3.2 GERMANY
    • 13.3.2.1 Expertise in biotechnology and reputation as leading pharmaceutical manufacturing hub to expedite market growth
  • 13.3.3 UK
    • 13.3.3.1 Growing R&D initiatives for development of GLP-1 agonists drugs to support market growth
  • 13.3.4 FRANCE
    • 13.3.4.1 Favorable regulatory scenario and strong research infrastructure to propel market growth
  • 13.3.5 ITALY
    • 13.3.5.1 Presence of key pharmaceutical & biotechnology companies to boost market growth
  • 13.3.6 SPAIN
    • 13.3.6.1 High incidence of diabetes and obesity to augment market adoption of GLP-1 therapeutic drugs
  • 13.3.7 NETHERLANDS
    • 13.3.7.1 Strong focus on pharmaceutical R&D to support market growth
  • 13.3.8 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 13.4.2 CHINA
    • 13.4.2.1 Increasing endorsements of anti-obesity drugs by celebrities to drive market adoption
  • 13.4.3 JAPAN
    • 13.4.3.1 High diabetic population and favorable regulatory scenario to aid market growth
  • 13.4.4 INDIA
    • 13.4.4.1 Growing demand for cost-effective and accessible anti-obesity medications to aid market growth
  • 13.4.5 AUSTRALIA
    • 13.4.5.1 Significant government investment in obesity prevention to fuel market growth
  • 13.4.6 SOUTH KOREA
    • 13.4.6.1 Increasing strategic collaborations in obesity drugs to propel market growth
  • 13.4.7 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 13.5.2 BRAZIL
    • 13.5.2.1 Increasing partnerships with global pharmaceutical companies and rising diabetes cases to drive Brazilian market
  • 13.5.3 MEXICO
    • 13.5.3.1 Growing diabetes and obesity prevalence to support market growth
  • 13.5.4 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST
  • 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 13.6.2 GCC COUNTRIES
    • 13.6.2.1 Kingdom of Saudi Arabia
      • 13.6.2.1.1 Pricing oversight of Saudi Food and Drug Authority and strong sales from leading industry players to drive market
    • 13.6.2.2 UAE
      • 13.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to spur market growth
    • 13.6.2.3 Rest of GCC Countries
  • 13.6.3 REST OF MIDDLE EAST
• 13.7 AFRICA
  • 13.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH
  • 13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY STRATEGIES/RIGHT TO WIN
  • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 AGONISTS MARKET
• 14.3 REVENUE ANALYSIS, 2020-2024
• 14.4 MARKET SHARE ANALYSIS, 2024
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
• 14.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (WITH PRODUCTS IN PIPELINE), 2024
  • 14.6.1 STARS
  • 14.6.2 EMERGING LEADERS
  • 14.6.3 PERVASIVE PLAYERS
  • 14.6.4 PARTICIPANTS
  • 14.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 14.6.5.1 Company footprint
    • 14.6.5.2 Region footprint
    • 14.6.5.3 Format footprint
    • 14.6.5.4 Route of administration footprint
    • 14.6.5.5 Indication footprint
• 14.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 14.7.1 PROGRESSIVE COMPANIES
  • 14.7.2 RESPONSIVE COMPANIES
  • 14.7.3 DYNAMIC COMPANIES
  • 14.7.4 STARTING BLOCKS
  • 14.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 14.7.5.1 Competitive benchmarking of key startups/SMEs
• 14.8 COMPANY VALUATION & FINANCIAL METRICS
  • 14.8.1 FINANCIAL METRICS
  • 14.8.2 COMPANY VALUATION
• 14.9 BRAND/PRODUCT COMPARISON
• 14.10 COMPETITIVE SCENARIO
  • 14.10.1 PRODUCT APPROVALS
  • 14.10.2 DEALS
  • 14.10.3 EXPANSIONS
  • 14.10.4 OTHER DEVELOPMENTS

15 COMPANY PROFILES

• 15.1 INTRODUCTION
• 15.2 KEY PLAYERS
  • 15.2.1 NOVO NORDISK A/S
    • 15.2.1.1 Business overview
    • 15.2.1.2 Products offered
    • 15.2.1.3 Recent developments
      • 15.2.1.3.1 Product approvals
      • 15.2.1.3.2 Deals
      • 15.2.1.3.3 Expansions
      • 15.2.1.3.4 Other developments
    • 15.2.1.4 MnM view
      • 15.2.1.4.1 Right to win
      • 15.2.1.4.2 Strategic choices
      • 15.2.1.4.3 Weaknesses & competitive threats
  • 15.2.2 ELI LILLY AND COMPANY
    • 15.2.2.1 Business overview
    • 15.2.2.2 Products offered
    • 15.2.2.3 Recent developments
      • 15.2.2.3.1 Product approvals
      • 15.2.2.3.2 Deals
      • 15.2.2.3.3 Expansions
    • 15.2.2.4 MnM view
      • 15.2.2.4.1 Right to win
      • 15.2.2.4.2 Strategic choices
      • 15.2.2.4.3 Weaknesses & competitive threats
  • 15.2.3 SANOFI
    • 15.2.3.1 Business overview
    • 15.2.3.2 Products offered
    • 15.2.3.3 MnM view
      • 15.2.3.3.1 Key strengths
      • 15.2.3.3.2 Strategic choices
      • 15.2.3.3.3 Weaknesses & competitive threats
  • 15.2.4 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
    • 15.2.4.1 Business overview
    • 15.2.4.2 Products offered
  • 15.2.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 15.2.5.1 Business overview
    • 15.2.5.2 Products offered (in pipeline)
    • 15.2.5.3 Recent developments
      • 15.2.5.3.1 Other developments
  • 15.2.6 INNOVENT
    • 15.2.6.1 Business overview
    • 15.2.6.2 Products offered (in pipeline)
    • 15.2.6.3 Recent developments
      • 15.2.6.3.1 Product approvals
      • 15.2.6.3.2 Other developments
  • 15.2.7 PEGBIO CO., LTD.
    • 15.2.7.1 Business overview
    • 15.2.7.2 Products offered (in pipeline)
  • 15.2.8 SCIWIND BIOSCIENCES CO., LTD.
    • 15.2.8.1 Business overview
    • 15.2.8.2 Products offered (in pipeline)
    • 15.2.8.3 Recent developments
      • 15.2.8.3.1 Deals
      • 15.2.8.3.2 Other developments
  • 15.2.9 ZEALAND PHARMA
    • 15.2.9.1 Business overview
    • 15.2.9.2 Products offered (in pipeline)
    • 15.2.9.3 Recent developments
      • 15.2.9.3.1 Deals
      • 15.2.9.3.2 Other developments
  • 15.2.10 STRUCTURE THERAPEUTICS, INC.
    • 15.2.10.1 Business overview
    • 15.2.10.2 Products offered (in pipeline)
    • 15.2.10.3 Recent developments
      • 15.2.10.3.1 Other developments
  • 15.2.11 VIKING THERAPEUTICS
    • 15.2.11.1 Business overview
    • 15.2.11.2 Products offered (in pipeline)
    • 15.2.11.3 Recent developments
      • 15.2.11.3.1 Deals
  • 15.2.12 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 15.2.12.1 Business overview
    • 15.2.12.2 Products offered (in pipeline)
  • 15.2.13 VTV THERAPEUTICS
    • 15.2.13.1 Business overview
    • 15.2.13.2 Products offered (in pipeline)
  • 15.2.14 ALTIMMUNE
    • 15.2.14.1 Business overview
    • 15.2.14.2 Products offered (in pipeline)
    • 15.2.14.3 Recent developments
      • 15.2.14.3.1 Other developments
  • 15.2.15 AMGEN INC.
    • 15.2.15.1 Business overview
    • 15.2.15.2 Products offered (in pipeline)
  • 15.2.16 GLENMARK PHARMACEUTICALS LTD.
    • 15.2.16.1 Business overview
    • 15.2.16.2 Products offered (in pipeline)
    • 15.2.16.3 Recent developments
      • 15.2.16.3.1 Product launches
  • 15.2.17 BIOCON
    • 15.2.17.1 Business overview
    • 15.2.17.2 Products offered (in pipeline)
    • 15.2.17.3 Recent developments
      • 15.2.17.3.1 Product launches and approvals
      • 15.2.17.3.2 Deals
  • 15.2.18 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 15.2.18.1 Business overview
    • 15.2.18.2 Products offered (in pipeline)
    • 15.2.18.3 Recent developments
      • 15.2.18.3.1 Product launches
  • 15.2.19 F. HOFFMANN-LA ROCHE LTD.
    • 15.2.19.1 Business overview
    • 15.2.19.2 Products offered (in pipeline)
    • 15.2.19.3 Recent developments
      • 15.2.19.3.1 Deals
• 15.3 OTHER PLAYERS
  • 15.3.1 TERNS PHARMACEUTICALS, INC.
  • 15.3.2 METAVIA
  • 15.3.3 SCOHIA PHARMA, INC.
  • 15.3.4 REGOR THERAPEUTICS GROUP
  • 15.3.5 NEURALY INC.
  • 15.3.6 I2O THERAPEUTICS, INC.
  • 15.3.7 PFIZER INC.
  • 15.3.8 HANMI PHARM CO.,LTD.
  • 15.3.9 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
  • 15.3.10 BIOMED INDUSTRIES, INC.

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS